MICRA 2026: The New Cap Math and Multi-Defendant Stacking
AB 35 took effect January 1, 2026, launching a ten-year phase-in of California's revised MICRA caps. The non-fatal non-economic damages cap opens at $470,000 and climbs $40,000 annually, reaching $750,000 by 2033. The wrongful death non-economic cap opens at $650,000, rising $50,000 per year to $1 million by 2033.
The structural change counsel cannot overlook is category stacking. Each of three defendant classes, individual physician or provider, hospital or medical institution, and unaffiliated provider such as an ambulance service, carries its own separate cap. In a fully stacked multi-defendant case the theoretical non-economic ceiling reaches roughly $1.41 million for non-fatal injury and $1.95 million for wrongful death.
Economic damages remain fully uncapped under both the old and new MICRA frameworks. Lifetime medical care, lost earning capacity, and future rehabilitation costs still function as the primary lever for case value in California, meaning life-care planner testimony and vocational economist reports carry even more weight than cap-driven headlines suggest.
Pleading strategy follows directly from the stacking math. Naming separate institutional and individual defendants, where facts support distinct standard-of-care theories, can multiply the non-economic recovery ceiling, but each theory must independently survive demurrer rather than functioning as a pass-through claim.
Counsel modeling 2026 California med-mal exposure should treat the three-category stack, not the headline cap figure, as the real valuation variable.
The Survival Action Reversal Nobody Budgeted For
California's temporary expansion allowing non-economic damages in survival actions expired January 1, 2026. Senate Bill 29, which sought a one-year extension through January 2027, failed after medical industry opposition, leaving no transition cushion for firms that built case strategy around the expanded version.
Survival actions now revert to economic and punitive damages only. Pain, suffering, and disfigurement recoveries are available solely through a wrongful death claim brought by statutory heirs, not through the decedent's estate.
Cases involving a decedent who survived the injury for a period before death now require careful allocation. Non-economic claims route to wrongful death and its separate cap, while pre-death medical bills and lost earnings route to the survival action, which carries no non-economic ceiling because none applies to economic damages.
Pending filings made before January 1, 2026 raise a retroactivity question that has not been resolved at the appellate level. Expect motion practice through 2026 and into 2027 on whether the expansion applies to injuries occurring before expiration but litigated after.
Firms with open California survival actions should audit pleadings now rather than waiting for an appellate answer on retroactivity.
Nuclear Verdicts Testing the New Framework
A Sacramento County jury returned $110 million in 2026 for the family of Mildred Hernandez, a 100-year-old assisted living resident who wandered outside her facility and died of exposure to freezing temperatures. The award, reported as the largest California care-facility verdict of the year, was driven primarily by uncapped economic damages tied to a lifetime care projection, with non-economic awards layered against multiple institutional defendants.
In Solano County, a jury awarded $15.75 million to the family of Ruby Evans, 96, who developed a severe pressure ulcer during a one-week stay at Windsor Vallejo Care Center in 2019. MICRA analysis applies given the institutional defendant, and the case is a candidate for testing the new stacking provision if additional defendants are named on remand or appeal.
Outside California, a Philadelphia County jury awarded $35 million to Isis Spencer, 45, who underwent a full hysterectomy after being told she had advanced endometrial cancer. Post-operative pathology confirmed she never had cancer, placing the case squarely in the wrongful surgical intervention category with no cap ceiling limiting the award.
Benchmarking California outcomes against cap-free jurisdictions like Pennsylvania remains useful for forum analysis, lien sizing, and settlement posture even where venue is fixed, since defense carriers increasingly reference national severity trends in negotiation.
The Hernandez verdict confirms that uncapped economic damages, not the non-economic cap, remain the dominant driver of California nuclear verdicts in 2026.
FDA Device Recalls and the Standard-of-Care Gap
October 2026 brought a cluster of device actions relevant to malpractice counsel: an ICU Medical IV tubing set correction, a BD/CareFusion infusion set recall, a Draeger breathing circuit recall, and a Medtronic/Given Imaging esophageal pH monitoring capsule delivery device removal.
GAO report 26-107619, issued this year, found that FDA's device-recall oversight has material limitations and recommended HHS address the gaps. Counsel litigating failure-to-act theories now have a federal oversight finding to corroborate claims that providers cannot rely on recall notice alone as a defense.
Surgery centers and hospitals face direct exposure for failing to act promptly once a recall notice issues. Discovery in these cases should target the gap between recall notice receipt date and the date the device was actually pulled from clinical use.
Medical providers listed in lien and referral directories should document their recall-compliance protocols now. A written log showing prompt removal of recalled inventory is the single most useful exhibit when a malpractice claim later surfaces tied to one of these device families.
The GAO finding on FDA oversight gaps gives counsel a federal record to anchor failure-to-act claims against providers who delayed recall response.
Premium Pressure Reshaping Settlement Posture
AMA Medical Liability Monitor data released this year marks the seventh consecutive year of medical professional liability premium increases, and the eleventh straight year that a majority of MPL filings trended upward nationally.
Projections call for 6 to 12 percent annual premium increases over the next two to three years. Non-cap states and high-risk specialties, particularly OB/GYN, neurosurgery, and orthopedics, face double-digit jumps attributed to nuclear verdict severity and broader social inflation in jury awards.
For counsel, the practical effect shows up in carrier behavior at the negotiating table. Insurers in non-cap jurisdictions facing sustained loss severity are increasingly motivated toward earlier resolution, while California carriers are beginning to price MICRA stacking exposure into 2026 renewal cycles.
Firms that track carrier loss-trend data by specialty and jurisdiction gain real leverage in demand letters, since citing documented premium escalation alongside case-specific damages strengthens the argument for early settlement authority.
Rising premiums in non-cap states are already shifting carrier settlement timing, and California MICRA stacking is starting to show up in the same underwriting conversation.
Lien Operations: Depo-Provera MDL and the Reduction Playbook
MDL 3140, the Depo-Provera meningioma litigation pending before Judge M. Casey Rodgers in the Northern District of Florida, produced a Master Settlement Agreement on July 21, 2026 covering approximately 80 percent of the 6,294 pending claimants per the August 3 JPML report. The settlement amount has not been disclosed, the general causation Daubert hearing concluded July 27, and the Toney bellwether trial was vacated.
Medical providers who administered Depo-Provera injections should monitor MSA opt-in and opt-out timelines closely. As settlements begin to disburse, lien-resolution obligations will follow on a schedule that providers listed in referral and lien directories need to track rather than discover after the fact.
General hospital lien reductions continue to run 30 to 50 percent off billed amounts in negotiation. Medicare conditional payments reduce under the 42 C.F.R. 411.37 procurement-cost formula proportional to attorney fees and litigation costs, while ERISA self-funded plan liens remain constrained by federal preemption, though ambiguous plan language on made-whole or common-fund waivers continues to function as a valid reduction lever.
A Q1 2026 case study from a twelve-attorney Texas PI firm using AI-assisted lien review showed median Medicare demand time dropping from 8.2 to 3.1 weeks and average lien reduction improving from 31 to 47 percent, producing roughly $2.4 million in net additional annualized client recovery.
Providers and firms benchmarking lien turnaround against the 3.1-week Medicare demand figure now have a concrete 2026 operational target.